Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCeriBell, Inc

CeriBell, Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
26.59 USD 0.58 ( 2.23%)
Last update at 2026-11-06T21:00:00Z
VOLUME
436387
Market Cap
793.05M

Momentum Score

…

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
24.87
Low
26.79
High
52 Week Price Range
10.85
Low
24.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CeriBell, Inc. develops portable EEG systems and software for rapid seizure detection and monitoring in acute care settings. Long-term growth could be driven by wider adoption of point-of-care EEG, demographic trends increasing neurological demand, international expansion, and improved reimbursement, which may appeal to investors seeking exposure to neurodiagnostic device adoption.
Key risks include commercial execution against established competitors, dependence on reimbursement and regulatory outcomes, and possible financing or profitability pressure during scale-up.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
26.01
Dividend Yield
-
Revenue TTM
89.06M
Revenue Per Share
2.44
Gross Profit TTM
78.27M
Debt / Equity
0.14
ROE
-30.83%
Net Debt
-18.20M
ROCE
-33.07%
Diluted EPS TTM
-1.46

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -53.41M -40.45M -29.45M -37.16M
Net income -53.41M -40.45M -29.46M -37.16M
Selling general administrative 44.45M 33.84M 59.21M 50.27M
Selling and marketing expenses 73.08M 49.05M - -
Gross profit 78.27M 56.75M 38.16M 21.49M
Reconciled depreciation 1.34M 1.14M 0.85M 0.50M
Ebit - -38.46M - -
Ebitda -51.52M -37.32M - -
Depreciation and amortization - 1.14M - -
Operating income -58.40M -39.71M -30.04M -36.02M
Other operating expenses 147.47M 105.15M - -
Interest expense 1.89M 1.99M 2.10M 1.60M
Tax provision 0.00M 0.00M 0.01M 0.00M
Net interest income -1.89M -1.99M -2.10M -1.60M
Total revenue 89.06M 65.44M 45.23M 25.92M
Total operating expenses 136.68M 96.46M 75.27M 61.94M
Cost of revenue 10.79M 8.69M 7.06M 4.43M
Total other income expense net 4.99M -0.75M 2.69M 0.46M
Net income from continuing ops -53.41M -40.45M -29.46M -37.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 195.80M 225.41M 58.92M 86.46M
Intangible assets 0.81M 0.47M - -
Other current assets 5.12M 5.09M 2.13M 1.17M
Total liab 40.47M 34.25M 171.17M 172.86M
Total stockholder equity 155.34M 191.16M -112.25M -86.40M
Other current liab 15.25M 10.66M 0.59M 0.15M
Common stock 0.04M 0.04M - -
Capital stock 0.04M 0.04M 0.01M 0.01M
Retained earnings -220.36M -166.94M -126.49M -97.03M
Cash 40.48M 194.37M 34.49M 68.23M
Total current liabilities 19.19M 12.99M 21.60M 9.86M
Current deferred revenue - 0.10M - -
Net debt -18.20M -172.41M - -
Short term debt 1.10M 1.09M - -
Short long term debt - - 11.83M 2.50M
Short long term debt total 22.28M 21.96M - -
Other stockholder equity 375.50M 358.07M - -
Total current assets 186.72M 217.27M 51.96M 79.80M
Short term investments 118.78M 0.00M - -
Net receivables 15.05M 10.88M 7.96M 5.29M
Long term debt 19.81M 19.56M - 12.72M
Inventory 7.29M 6.94M 5.87M 4.08M
Accounts payable 2.84M 1.14M 0.73M 0.42M
Accumulated other comprehensive income 0.16M - - -
Non currrent assets other 3.95M 3.69M 1.98M 1.83M
Non current assets total 9.09M 8.14M 6.96M 6.66M
Capital lease obligations 2.46M 2.40M 2.37M 3.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -116.61M -1.60M -1.76M -1.40M
Total cashflows from investing activities -118.14M -1.60M - -
Net borrowings 0.00M 7.91M - -
Total cash from financing activities 5.05M 196.52M -2.82M 49.80M
Net income -53.41M -40.45M -29.46M -37.16M
Change in cash -153.89M 159.88M -33.74M 16.40M
Begin period cash flow 194.37M 34.49M 68.23M 51.83M
End period cash flow 40.48M 194.37M 34.49M 68.23M
Total cash from operating activities -40.81M -35.04M -29.16M -32.00M
Issuance of capital stock 0.00M 192.83M 0.00M 50.00M
Depreciation -0.67M 1.14M 0.85M 0.50M
Other cashflows from investing activities -0.76M -0.26M - -
Change to inventory -0.35M -1.07M -1.79M -1.90M
Change to account receivables -4.17M -3.51M -2.66M -3.06M
Sale purchase of stock - - 0.00M -0.31M
Other cashflows from financing activities -0.39M -0.30M - -
Capital expenditures 0.77M 1.34M 0.98M 0.52M
Change in working capital 0.63M -3.17M -3.70M -3.88M
Stock based compensation 12.22M 5.41M 2.68M 7.93M
Other non cash items 0.42M 2.03M 0.34M 0.35M
Free cash flow -41.58M -36.38M -30.14M -32.52M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
CBLL
CeriBell, Inc		 0.58
2.23%		 26.59 - - 8.90 5.10 7.36
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95

Profile*

CeriBell, Inc

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.

360 North Pastoria Avenue, Sunnyvale, CA, United States, 94085

800 436 0826

https://www.ceribell.com

327

Name Title Year Born
Dr. Xingjuan Chao Ph.D. Co-Founder, President, CEO & Director 1980
Dr. Josef Parvizi M.D., Ph.D. Co-Founder, Chief Medical Advisor & Director 1968
Mr. Scott Blumberg Chief Financial Officer NA
Dr. Raymond Woo Ph.D. Chief Technology Officer 1982
Mr. Joshua Copp Chief Business Officer 1985
Mr. Dan Rogy Senior Vice President of Operations NA
David Foehr Senior VP, Finance and PAO NA
Ms. Louisa Daniels J.D., M.B.A. General Counsel 1958
Mr. Sean Manni Senior Vice President of Sales NA
Mr. Brian P. Price Senior Vice President of Marketing NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…